Vicore announces new data from the IPF AIR trial further strengthening the benefit-risk profile of C21
· The new results show stabilization of disease already from week 6 and confirm the unprecedented increase in lung function over time · Vicore will accelerate clinical development · Invitation to conference call on November 4 at 13:00 CET/8:00 am EST
Stockholm, November 3, 2022 – Vicore Pharma Holding AB (publ) (“Vicore” or the “Company”), a pioneer in the development of angiotensin II type 2 receptor agonists (ATRAGs), provides a new interim analysis of the ongoing AIR trial, a phase 2a study in idiopathic pulmonary fibrosis (IPF).
The AIR trial[1] is a multi-center open label